Homing in on delivery
The scientific community now seems convinced that small RNAs will become therapies, if new tools can help these large molecules to make it safely into cells. Monya Baker reports.
Researchers in the field of small RNAs have been on a wild ride. Twenty years ago, RNA was considered a passive conveyer of information between DNA and protein. Now it is understood that RNA controls and coordinates almost everything that goes on in a cell. From being long unrecognized, then heralded as a convenient tool for screening gene function, small RNAs are now hotly pursued as therapies.
Advocates of using small RNAs to treat disease like to tick off the hurdles that were anticipated but seem to have been cleared: that the computational techniques for predicting appropriate RNA sequences would be overwhelming, that synthetic oligonucleotides would be too expensive to manufacture, that the problems uncovered with earlier RNA drugs would crop up again, and that there would be no way of mitigating 'off-target' (or nonspecific) effects.
The field has moved fast. The complex process by which small RNAs are able to silence genes by targeting complementary messenger RNA molecules for destruction was recognized and named RNA interference (RNAi) in 1998 (ref. 1). In 2004, the first RNAi-based experimental therapies entered clinical trials.
For the past few years, though, researchers 
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